Browse by Journal Title

2023

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen, A., Ben Hamza, A., Welters, C., Dietze, K., Bullinger, L., Rahn, H.P., Hartmann, S., Hansmann, M.L. and Hansmann, L.
Cancer Immunology Immunotherapy 72 (2): 515-521. February 2023

2022

Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
Kursunel, M.A., Taskiran, E.Z., Tavukcuoglu, E., Yanik, H., Demirag, F., Karaosmanoglu, B., Ozbay, F.G., Uner, A., Esendagli, D., Kizilgoz, D., Yilmaz, U. and Esendagli, G.
Cancer Immunology Immunotherapy 71 (2): 445-459. February 2022

2020

Prostaglandin E(2) in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8(+) T cells.
Gierlich, P., Lex, V., Technau, A., Keupp, A., Morper, L., Glunz, A., Sennholz, H., Rachor, J., Sauer, S., Marcu, A., Grigoleit, G.U., Wölfl, M., Schlegel, P.G. and Eyrich, M.
Cancer Immunology Immunotherapy 69 (6): 1029-1042. June 2020

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner, J., Götz, M., Hofmann, S., Schrezenmeier, H., Wiesneth, M., Bullinger, L., Döhner, H. and Schneider, V.
Cancer Immunology Immunotherapy 69 (4): 629-640. April 2020

2018

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber, A.N.R., Cardona Gloria, Y., Çınar, Ö., Reinhardt, H.C., Pezzutto, A. and Wolz, O.O.
Cancer Immunology Immunotherapy 67 (11): 1797-1807. November 2018

2015

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
Stermann, A., Huebener, N., Seidel, D., Fest, S., Eschenburg, G., Stauder, M., Schramm, A., Eggert, A. and Lode, H.N.
Cancer Immunology Immunotherapy 64 (10): 1215-1227. October 2015

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel, D., Shibina, A., Siebert, N., Wels, W.S., Reynolds, C.P., Huebener, N. and Lode, H.N.
Cancer Immunology Immunotherapy 64 (5): 621-634. May 2015

2009

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.
Uckert, W. and Schumacher, T.N.
Cancer Immunology Immunotherapy 58 (5): 809-822. May 2009

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani, S., Triulzi, C., Roos, A.K., Charo, J., Norell, H., Lemonnier, F., Pisa, P., Seliger, B. and Kiessling, R.
Cancer Immunology Immunotherapy 58 (5): 653-664. May 2009

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
Schulze, T., Kemmner, W., Weitz, J., Wernecke, K.D., Schirrmacher, V. and Schlag, P.M.
Cancer Immunology Immunotherapy 58 (1): 61-69. January 2009

2007

The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs.
Ravn, P., Stahn, R., Danielczyk, A., Faulstich, D., Karsten, U. and Goletz, S.
Cancer Immunology Immunotherapy 56 (9): 1345-1357. September 2007

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells.
Na, I.K., Keilholz, U., Letsch, A., Bauer, S., Asemissen, A.M., Nagorsen, D., Thiel, E. and Scheibenbogen, C.
Cancer Immunology Immunotherapy 56 (3): 391-396. March 2007

2006

PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk, A., Stahn, R., Faulstich, D., Loeffler, A., Maerten, A., Karsten, U. and Goletz, S.
Cancer Immunology Immunotherapy 55 (11): 1337-1347. November 2006

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., Silva, A.D., Locher, M., Kischel, R., Lutterbuese, R., Kufer, P. and Baeuerle, P.A.
Cancer Immunology Immunotherapy 55 : 785-796. July 2006

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth, B., Quadt, C., Dreier, T., Kufer, P., Lorenczewski, G., Prang, N., Brandl, C., Lippold, S., Cobb, K., Brasky, K., Leo, E., Bargou, R., Murthy, K. and Baeuerle, P.A.
Cancer Immunology Immunotherapy 55 : 503-514. May 2006

2004

T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
Gruen, M., Bommert, K. and Bargou, R.C.
Cancer Immunology Immunotherapy 53 (7): 625-632. 1 January 2004

2003

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.
Westermann, J., Koerner, I.J., Kopp, J., Kurz, S., Zenke, M., Doerken, B. and Pezzutto, A.
Cancer Immunology Immunotherapy 52 (3): 194-198. March 2003

2002

Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial.
Pecher, G., Haering, A., Kaiser, L. and Thiel, E.
Cancer Immunology Immunotherapy 51 (11-12): 669-673. December 2002

2001

Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).
Johnen, H., Kulbe, H. and Pecher, G.
Cancer Immunology Immunotherapy 50 : 356-360. 1 January 2001

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann, J., Reich, G., Kopp, J., Haus, U., Doerken, D. and Pezzutto, A.
Cancer Immunology Immunotherapy 49 : 613-620. 1 January 2001

1997

A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis.
Jerome, K.R., Kirk, A.D., Pecher, G., Ferguson, W.W. and Finn, O.J.
Cancer Immunology Immunotherapy 43 : 355-360. 1 January 1997

1993

Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts.
Schmid, J., Moeller, P., Moldenhauer, G., Doerken, B., Bihl, H. and Matzku, S.
Cancer Immunology Immunotherapy 36 : 274-280. 1 January 1993

In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.
Stoeck, M., Marland-Noske, C., Manasterski, M., Zawatzky, R., Horn, S., Moebus, V., Schlag, P.M. and Schirrmacher, V.
Cancer Immunology Immunotherapy 37 : 240-244. 1 January 1993

1992

Active specific immunotherapy with Newcastle-disease-virus modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
Schlag, P.M., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W. and Schirrmacher, V.
Cancer Immunology Immunotherapy 35 (5): 325-330. 1 May 1992